FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040421189> ?p ?o ?g. }

• W2040421189 endingPage "811" @default.
• W2040421189 startingPage "799" @default.
• W2040421189 abstract "This randomized clinical trial is designed to assess whether the prevention and/or correction of anemia, by immediate versus delayed treatment with erythropoietin alfa in patients with chronic kidney disease, would delay left ventricular (LV) growth. Study design and sample size calculations were based on previously published Canadian data.One hundred seventy-two patients were randomly assigned. The treatment group received therapy with erythropoietin alfa subcutaneously to maintain or achieve hemoglobin (Hgb) level targets of 12.0 to 14.0 g/dL (120 to 140 g/L). The control/delayed treatment group had Hgb levels of 9.0 +/- 0.5 g/dL (90 +/- 5 g/L) before therapy was started: target level was 9.0 to 10.5 g/dL (90 to 105 g/L). Optimal blood pressure and parathyroid hormone, calcium, and phosphate level targets were prescribed; all patients were iron replete. The primary end point is LV growth at 24 months.One hundred fifty-two patients were eligible for the intention-to-treat analysis: mean age was 57 years, 30% were women, 38% had diabetes, and median glomerular filtration rate was 29 mL/min (0.48 mL/s; range, 12 to 55 mL/min [0.20 to 0.92 mL/s]). Blood pressure and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use were similar in the control/delayed treatment and treatment groups at baseline. Erythropoietin therapy was administered to 77 of 78 patients in the treatment group, with a median final dose of 2,000 IU/wk. Sixteen patients in the control/delayed treatment group were administered erythropoietin at a median final dose of 3,000 IU/wk. There was no statistically significant difference between groups for the primary outcome of mean change in LV mass index (LVMI) from baseline to 24 months, which was 5.21 +/- 30.3 g/m2 in the control/delayed treatment group versus 0.37 +/- 25.0 g/m2 in the treatment group. Absolute mean difference between groups was 4.85 g/m2 (95% confidence interval, -4.0 to 13.7; P = 0.28). Mean Hgb level was greater in the treatment group throughout the study and at study end was 12.75 g/dL (127.5 g/L in treatment group versus 11.46 g/dL [114.6 g/L] in control/delayed treatment group; P = 0.0001). LV growth occurred in 20.1% in the treatment group versus 31% in the control/delayed treatment group (P = 0.136). In patients with a stable Hgb level, mean LVMI did not change (-0.25 +/- 26.7 g/m2), but it increased in those with decreasing Hgb levels (19.3 +/- 28.2 g/m2; P = 0.002).This trial describes disparity between observational and randomized controlled trial data: observed and randomly assigned Hgb level and LVMI are not linked; thus, there is strong evidence that the association between Hgb level and LVMI likely is not causal. Large randomized controlled trials with unselected patients, using morbidity and mortality as outcomes, are needed." @default.
• W2040421189 created "2016-06-24" @default.
• W2040421189 creator A5010752000 @default.
• W2040421189 creator A5015496748 @default.
• W2040421189 creator A5016353371 @default.
• W2040421189 creator A5017164111 @default.
• W2040421189 creator A5027138774 @default.
• W2040421189 creator A5032482746 @default.
• W2040421189 creator A5035233272 @default.
• W2040421189 creator A5035956975 @default.
• W2040421189 creator A5038407839 @default.
• W2040421189 creator A5046130400 @default.
• W2040421189 creator A5046341729 @default.
• W2040421189 creator A5048627273 @default.
• W2040421189 creator A5053291645 @default.
• W2040421189 creator A5057348971 @default.
• W2040421189 creator A5060743661 @default.
• W2040421189 creator A5075739831 @default.
• W2040421189 creator A5077926834 @default.
• W2040421189 creator A5078698621 @default.
• W2040421189 creator A5086766337 @default.
• W2040421189 date "2005-11-01" @default.
• W2040421189 modified "2023-10-05" @default.
• W2040421189 title "Canadian Randomized Trial of Hemoglobin Maintenance to Prevent or Delay Left Ventricular Mass Growth in Patients With CKD" @default.
• W2040421189 cites W1969651149 @default.
• W2040421189 cites W1973079507 @default.
• W2040421189 cites W1996698106 @default.
• W2040421189 cites W2016046345 @default.
• W2040421189 cites W2042293234 @default.
• W2040421189 cites W2056814323 @default.
• W2040421189 cites W2061569406 @default.
• W2040421189 cites W2071729123 @default.
• W2040421189 cites W2083403848 @default.
• W2040421189 cites W2088293785 @default.
• W2040421189 cites W2124185743 @default.
• W2040421189 cites W2128661749 @default.
• W2040421189 cites W2143753157 @default.
• W2040421189 cites W2169588753 @default.
• W2040421189 cites W2170810459 @default.
• W2040421189 cites W2990123797 @default.
• W2040421189 cites W4205330182 @default.
• W2040421189 cites W424467158 @default.
• W2040421189 doi "https://doi.org/10.1053/j.ajkd.2005.08.007" @default.
• W2040421189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16253719" @default.
• W2040421189 hasPublicationYear "2005" @default.
• W2040421189 type Work @default.
• W2040421189 sameAs 2040421189 @default.
• W2040421189 citedByCount "184" @default.
• W2040421189 countsByYear W20404211892012 @default.
• W2040421189 countsByYear W20404211892013 @default.
• W2040421189 countsByYear W20404211892014 @default.
• W2040421189 countsByYear W20404211892015 @default.
• W2040421189 countsByYear W20404211892016 @default.
• W2040421189 countsByYear W20404211892017 @default.
• W2040421189 countsByYear W20404211892018 @default.
• W2040421189 countsByYear W20404211892019 @default.
• W2040421189 countsByYear W20404211892020 @default.
• W2040421189 countsByYear W20404211892021 @default.
• W2040421189 countsByYear W20404211892022 @default.
• W2040421189 countsByYear W20404211892023 @default.
• W2040421189 crossrefType "journal-article" @default.
• W2040421189 hasAuthorship W2040421189A5010752000 @default.
• W2040421189 hasAuthorship W2040421189A5015496748 @default.
• W2040421189 hasAuthorship W2040421189A5016353371 @default.
• W2040421189 hasAuthorship W2040421189A5017164111 @default.
• W2040421189 hasAuthorship W2040421189A5027138774 @default.
• W2040421189 hasAuthorship W2040421189A5032482746 @default.
• W2040421189 hasAuthorship W2040421189A5035233272 @default.
• W2040421189 hasAuthorship W2040421189A5035956975 @default.
• W2040421189 hasAuthorship W2040421189A5038407839 @default.
• W2040421189 hasAuthorship W2040421189A5046130400 @default.
• W2040421189 hasAuthorship W2040421189A5046341729 @default.
• W2040421189 hasAuthorship W2040421189A5048627273 @default.
• W2040421189 hasAuthorship W2040421189A5053291645 @default.
• W2040421189 hasAuthorship W2040421189A5057348971 @default.
• W2040421189 hasAuthorship W2040421189A5060743661 @default.
• W2040421189 hasAuthorship W2040421189A5075739831 @default.
• W2040421189 hasAuthorship W2040421189A5077926834 @default.
• W2040421189 hasAuthorship W2040421189A5078698621 @default.
• W2040421189 hasAuthorship W2040421189A5086766337 @default.
• W2040421189 hasConcept C126322002 @default.
• W2040421189 hasConcept C126894567 @default.
• W2040421189 hasConcept C134018914 @default.
• W2040421189 hasConcept C141071460 @default.
• W2040421189 hasConcept C159641895 @default.
• W2040421189 hasConcept C168563851 @default.
• W2040421189 hasConcept C2776002628 @default.
• W2040421189 hasConcept C2778248108 @default.
• W2040421189 hasConcept C2778534260 @default.
• W2040421189 hasConcept C2778653478 @default.
• W2040421189 hasConcept C2778917026 @default.
• W2040421189 hasConcept C2781404941 @default.
• W2040421189 hasConcept C2908929049 @default.
• W2040421189 hasConcept C555293320 @default.
• W2040421189 hasConcept C71924100 @default.
• W2040421189 hasConcept C84393581 @default.
• W2040421189 hasConcept C90924648 @default.
• W2040421189 hasConceptScore W2040421189C126322002 @default.

• next